Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.01)
# 2,746
Out of 4,413 analysts
32
Total ratings
27.27%
Success rate
-11.68%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PSTX Poseida Therapeutics | Reiterates: Overweight | $14 | $2.77 | +405.42% | 2 | Oct 10, 2023 | |
| INSM Insmed | Maintains: Overweight | $46 → $54 | $25.59 | +111.02% | 5 | Sep 21, 2023 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | $31 | $18.04 | +71.84% | 4 | Sep 14, 2023 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.39 | +43.88% | 2 | Aug 31, 2023 | |
| FBIO Fortress Biotech | Reiterates: Overweight | $75 | $1.74 | +4,210.34% | 3 | Aug 15, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $1.40 | +900.00% | 4 | Aug 15, 2023 | |
| BLTE Belite Bio | Initiates: Overweight | $43 | $41.02 | +4.83% | 1 | Jul 28, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $4.71 | +600.64% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.00 | +125.00% | 2 | May 17, 2023 | |
| ALLK Allakos | Reiterates: Overweight | $7 | $1.13 | +519.47% | 3 | Mar 7, 2023 | |
| PGEN Precigen | Maintains: Overweight | $7 → $10 | $1.40 | +614.29% | 2 | Jan 30, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.89 | +3,356.50% | 2 | May 17, 2022 |
Poseida Therapeutics
Oct 10, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.77
Upside: +405.42%
Insmed
Sep 21, 2023
Maintains: Overweight
Price Target: $46 → $54
Current: $25.59
Upside: +111.02%
EyePoint Pharmaceuticals
Sep 14, 2023
Reiterates: Overweight
Price Target: $31
Current: $18.04
Upside: +71.84%
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.39
Upside: +43.88%
Fortress Biotech
Aug 15, 2023
Reiterates: Overweight
Price Target: $75
Current: $1.74
Upside: +4,210.34%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $1.40
Upside: +900.00%
Belite Bio
Jul 28, 2023
Initiates: Overweight
Price Target: $43
Current: $41.02
Upside: +4.83%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $4.71
Upside: +600.64%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.00
Upside: +125.00%
Allakos
Mar 7, 2023
Reiterates: Overweight
Price Target: $7
Current: $1.13
Upside: +519.47%
Precigen
Jan 30, 2023
Maintains: Overweight
Price Target: $7 → $10
Current: $1.40
Upside: +614.29%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.89
Upside: +3,356.50%